The TTR Amyloidosis Disease Cascade and Why It Demands Multi-Modal Intervention
Transthyretin (TTR) amyloidosis (ATTR) is a progressive systemic disease in which misfolding and aggregation of the TTR protein — a hepatically secreted homotetramer — leads to amyloid fibril deposition in cardiac, neurological, and other tissues. The disease mechanism is well-characterised across retrieved patent filings: the TTR tetramer dissociates into monomers that misfold and aggregate into amyloid fibrils, which then deposit in organs. In hereditary ATTR (hATTR), over 100 documented TTR gene mutation variants destabilise the tetramer and accelerate this process; in wild-type ATTR (wtATTR), normal TTR protein becomes unstable with aging.
Two predominant clinical phenotypes drive the therapeutic need: ATTR cardiomyopathy (ATTR-CM), characterised by amyloid fibril deposition in cardiac tissue, and ATTR polyneuropathy (ATTR-PN), caused by fibril deposition in peripheral and autonomic nerve tissue. Additional manifestations cited in retrieved filings include CNS/leptomeningeal amyloidosis, ocular amyloidosis, renal amyloidosis, carpal tunnel syndrome, and rotator cuff pathology. Diagnostic patent filings from the University of Tennessee Research Foundation note that up to 25% of ATTR amyloidosis patients die within 24 months of diagnosis under current therapies — a statistic that contextualises the urgency of next-generation pipeline development.
ATTR amyloidosis presents in two distinct forms: hereditary ATTR (hATTR), driven by over 100 documented TTR gene mutations that destabilise the TTR tetramer, and wild-type ATTR (wtATTR), in which normal TTR protein becomes unstable with aging — both causing amyloid fibril deposition in cardiac and neurological tissues.
Because the amyloidogenic cascade involves multiple discrete steps — TTR expression, tetramer stability, monomer misfolding, fibril aggregation, and organ deposition — therapeutic intervention is being pursued at each stage. According to WIPO patent data, this multi-step disease mechanism has generated one of the most intellectually diverse small-molecule and biologic pipelines in rare cardiovascular disease. The result is a patent landscape spanning at least four mechanistically distinct modalities, with combination strategies now emerging as an active IP battleground.
TTR is a homotetrameric protein produced primarily by the liver, responsible for transporting thyroxine and retinol in blood and cerebrospinal fluid. Under conditions potentially including acidic pH and oxidative stress, the tetramer dissociates into monomers that misfold and aggregate into amyloid fibrils — depositing in cardiac, neurological, and other organ tissues. Therapeutic strategies target every step of this cascade.
RNAi Silencers and Small-Molecule Stabilizers: The Established Modalities
The two most clinically validated ATTR modalities in the retrieved patent dataset are TTR gene silencing via RNA interference (RNAi) and TTR tetramer stabilisation via small molecules — both with active late-stage or approved agents and ongoing IP prosecution activity through 2026.
RNAi: Alnylam’s Dominant Silencing Portfolio
Alnylam Pharmaceuticals is the dominant assignee for TTR-directed RNAi in this dataset, holding filings across CA, WO, US, and JP jurisdictions. Their filings describe double-stranded RNAi agents targeting the TTR gene to reduce TTR expression in patients with hereditary or wild-type ATTR amyloidosis. One retrieved filing specifies a sense strand (SEQ ID NO: 10) and antisense strand (SEQ ID NO: 7) incorporating 2′-O-methyl (2′-OMe) and 2′-fluoro (2′-F) modifications, with phosphorothioate backbone linkages, administered as a fixed approximately 50 mg dose — a level of chemical detail characteristic of clinical-stage IP.
Alnylam Pharmaceuticals’ 2026 US continuation patent filing extends TTR-directed RNAi claims to both hereditary TTR-mediated amyloidosis and Stargardt disease, signalling potential label expansion beyond ATTR amyloidosis into ophthalmology.
A separate Alnylam filing establishes neurofilament light chain (NfL) as a pharmacodynamic biomarker for ATTR-PN, describing methods for selecting patients for TTR-silencing therapy based on elevated NfL relative to healthy controls, and for switching patients away from TTR stabilisation toward TTR silencing. This filing references clinical data from the inotersen Phase 3 trial (Benson et al., N Engl J Med 2018), reporting improvements in mNIS+7 score and Norfolk QOL-DN score, alongside serious adverse events including glomerulonephritis (3%) and thrombocytopenia (3%).
“The RNAi modality has the deepest clinical validation in this dataset, evidenced by referenced Phase 3 trial data, biomarker IP, and active US continuation filings through 2026 — indicating continued prosecution and potential claim broadening to new indications including Stargardt disease.”
Small-Molecule Stabilizers: Acoramidis and Next-Generation Scaffolds
Multiple retrieved patent families cover small-molecule stabilisers that bind at the thyroxine-binding sites of the TTR tetramer, kinetically stabilising the native assembly and minimising the pool of amyloidogenic monomers. Eidos Therapeutics (now part of BridgeBio) holds international filings in CA, IL, SG, and JP jurisdictions covering AG10 (acoramidis) with specific dosing regimens. A 2024 WO filing from Eidos specifically addresses TTR stabilisation in patients with TTR mutations, referencing acoramidis (identified as Compound 1) with efficacy and tolerability language consistent with clinical-stage data.
BSIM2 Biomolecular Simulations (Portugal) contributes a distinct pre-competitive IP layer with EP and WO filings covering two novel chemical scaffolds: bis-furan derivatives and 2-thioxothiazolidin-4-one derivatives. Retrieved data from BSIM2 filings describe in vitro results showing bis-furan compounds outperform tafamidis in inhibiting amyloid formation despite lower molecular weight and lipophilicity, with ex vivo confirmation in human plasma from FAP Val30Met-TTR carriers. A Rensselaer Polytechnic Institute filing adds a further dimension with a co-drug strategy conjugating a selective TTR ligand to a deuterated retinoid (C20-D3-retinol) for dual treatment of macular degeneration and TTR amyloidosis, targeting the RBP4-TTR interaction axis.
Map the full ATTR amyloidosis patent landscape — from TTR stabilisers to RNAi silencers — with PatSnap Eureka’s AI-powered drug intelligence.
Explore Patent Data in PatSnap Eureka →Anti-TTR Antibody Immunotherapy: The Dominant IP Cluster
Anti-TTR antibody immunotherapy represents the largest single cluster of ATTR-specific patent records in this dataset, with Neurimmune AG and its predecessor Neurimmune Holding AG holding active or pending patent families across US, EP, IL, SG, NZ, JP, CA, AU, WO, and CN jurisdictions spanning 2015–2025.
Neurimmune AG’s anti-TTR antibody NI006 (also identified as ALXN2220 in the Alexion/AstraZeneca co-development context) is described in a 2024 WO patent filing as depleting amyloid transthyretin from cardiac tissue in a dose- and time-dependent manner in adult patients with ATTR cardiomyopathy (ATTR-CM).
Neurimmune’s antibodies are described as human-derived, capable of binding misfolded, misassembled, and/or aggregated TTR species while not binding physiologically folded TTR tetramers. This conformational selectivity is framed as key to avoiding interference with the normal TTR transport function in the blood and cerebrospinal fluid. A 2025 JP filing from Neurimmune AG describes a clinical trial design with randomisation stratified by: (1) current disease-modifying agent use (TTR silencer ± TTR stabiliser vs. stabiliser alone vs. none), (2) TTR genotype (variant vs. wild-type), and (3) NT-proBNP-based disease severity — constituting a strong clinical translational signal.
Beyond Neurimmune, several other assignees contribute distinct antibody approaches. Prothena Biosciences holds IP covering antibodies targeting a “cryptic epitope” exposed only on monomeric and misfolded TTR (PRX004), with formulation patents covering lyophilised anti-TTR monoclonal antibody preparations. ADRX, Inc. holds patents on TTR monomer-specific antibodies as a mechanistically distinct approach, with WO (2023) and US (2025) filings. Novo Nordisk A/S holds pending CN and JP filings covering anti-TTR antibodies for detecting, reducing, and inhibiting misfolded TTR. According to NIH clinical trial registries, antibody-based clearance of amyloid deposits represents a rapidly maturing approach across systemic amyloidosis indications.
Neurimmune and Prothena filings both emphasise that their anti-TTR antibodies preferentially bind misfolded, misassembled, or aggregated TTR — rather than physiologically normal tetrameric TTR. This conformational selectivity is framed across retrieved filings as essential to avoiding interference with the normal TTR transport function for thyroxine and retinol.
CRISPR Gene Editing and Combination Strategies: The Emerging Frontier
CRISPR-based TTR gene editing and multi-modality combination approaches represent the two most forward-looking IP areas in the ATTR pipeline — one at an early preclinical stage, the other rapidly maturing into active clinical investigation.
CRISPR/Gene Editing: Intellia’s Early-Stage Position
Retrieved results include one patent from Intellia Therapeutics covering CRISPR-based editing of the TTR gene in the liver for treatment of ATTR amyloidosis. The patent covers compositions and methods for introducing double-strand breaks within the TTR gene using a guide RNA in combination with corticosteroid co-administration — to manage immune responses to viral delivery vectors. The filing is a continuation of PCT/US2020/025533 (priority 2019), active in the US jurisdiction. This is the only gene editing entry in this dataset, and no clinical data signals for CRISPR TTR editing were retrieved, positioning this modality as earlier-stage relative to the established antibody and small-molecule IP. The integration of corticosteroid co-administration into the gene editing protocol signals that immunomodulation is being built into in vivo CRISPR delivery from the outset.
Intellia Therapeutics holds the sole CRISPR gene editing patent for ATTR amyloidosis in the retrieved dataset, covering guide RNA-directed double-strand breaks within the TTR gene combined with corticosteroid co-administration to manage immune responses to viral delivery vectors. No clinical data signals for this modality were retrieved.
Combination Strategies: Antibody + Stabilizer and Beyond
Neurimmune AG holds multiple patent families (CA, IL, AU, JP, WO jurisdictions, filed 2020–2023) specifically claiming the combination of an anti-TTR antibody with a TTR tetramer stabiliser. The mechanistic rationale is explicitly stated in retrieved filings: stabilisers reduce amyloid precursor formation while antibodies clear existing deposits — addressing orthogonal aspects of the disease process. The 2025 Neurimmune JP clinical trial filing includes a stratification arm for patients receiving a TTR silencer plus TTR stabiliser, suggesting clinical investigation of up to three concurrent modalities in ATTR-CM.
The Prothena lyophilised formulation patent explicitly notes prior treatment with “TTR tetramer stabiliser, antisense oligonucleotide-based therapy, RNA interference-based therapy, or amyloid degrader” as relevant patient histories for anti-TTR antibody therapy — implying that combination or sequential use across modalities is being considered clinically. The BSIM2 bis-furan filing additionally discusses evidence implicating TTR stability in Alzheimer’s disease, suggesting a potential repositioning signal for TTR stabilisers beyond ATTR. The Rensselaer Polytechnic Institute co-drug filing (AU, 2026) represents the most structurally novel concept in this dataset: a bifunctional molecule targeting both TTR amyloidosis and retinal lipofuscin accumulation via the RBP4-TTR interaction axis, suggesting emergent dual-indication programmes. According to EMA regulatory frameworks, combination biologics and co-drug strategies require distinct regulatory pathways, adding a further dimension to the IP strategy in this space.
Identify freedom-to-operate risks and combination therapy IP gaps in the ATTR pipeline with PatSnap Eureka’s AI drug intelligence tools.
Analyse ATTR Patents in PatSnap Eureka →Assignee Landscape and Strategic IP Implications
The ATTR amyloidosis patent landscape is characterised by a small number of highly active commercial assignees, a handful of specialised biotechs, and emerging academic-to-industry translation — each occupying distinct modality niches with limited direct IP overlap at the composition-of-matter level.
Key Assignees and Their IP Positions
- Neurimmune AG / Neurimmune Holding AG (Switzerland): The highest-volume ATTR-specific assignee in this dataset, holding active or pending patents in US, EP, IL, SG, NZ, JP, CA, AU, WO, and CN jurisdictions for anti-TTR antibody therapy. Antibody NI006/ALXN2220 appears in multiple 2024–2025 filings. Combination therapy claims (antibody + stabiliser) represent a distinct IP cluster.
- Alnylam Pharmaceuticals (US): Multiple filings covering TTR-directed RNAi compositions with precisely defined nucleotide chemistry and dosing regimens in CA, WO, US, and JP jurisdictions. Also holds NfL biomarker IP. The 2026 US continuation filing is among the most recent in this dataset.
- Eidos Therapeutics / BridgeBio (US): Multiple international filings (CA, IL, SG, JP) covering acoramidis (AG10) with specific dosing regimens. The 2024 WO filing on acoramidis with specific TTR mutations is the most recent from this assignee.
- Prothena Biosciences (Ireland): Anti-TTR antibody (PRX004) IP in US, SG, CA, and JP jurisdictions. Also holds lyophilised formulation patent for anti-TTR monoclonal antibodies.
- BSIM2 Biomolecular Simulations LDA (Portugal): A specialised chemistry assignee with EP and WO filings on two distinct small-molecule TTR stabiliser scaffolds (bis-furan and thioxothiazolidinone), positioned preclinically.
- Intellia Therapeutics (US): Sole gene-editing assignee in this dataset, with CRISPR/guide RNA + corticosteroid TTR editing patent.
- ADRX, Inc. (US): Emerging antibody assignee targeting TTR monomers specifically, with WO (2023) and US (2025) filings.
- Novo Nordisk A/S (Denmark): Pending CN and JP filings on anti-TTR antibodies for misfolded TTR detection and inhibition.
Strategic Implications for IP Teams
IP strategists evaluating freedom-to-operate in anti-TTR antibody development should map the comprehensive Neurimmune Holding AG / Neurimmune AG patent estate across EP, US, IL, SG, NZ, JP, CA, AU, CN jurisdictions — the broadest international filing footprint in this dataset. The combination therapy IP space (antibody + stabiliser) represents an active and underappreciated battleground: Neurimmune’s combination claims and Prothena’s multi-modality treatment history references suggest that combination regimens will be a key area for both IP ownership and clinical differentiation in the next three to five years.
Drug developers evaluating CRISPR gene editing for ATTR should monitor the space for new entrants and assess whether Intellia’s guide RNA + corticosteroid co-administration claims create IP barriers for competing programmes. Second-generation small-molecule stabilisers (BSIM2 scaffolds) and novel TTR/RBP4 co-drugs represent pre-competitive IP that could attract partnership interest, particularly given their preclinical evidence of superior potency versus tafamidis. As noted by EPO patent analytics, rare disease indications with well-characterised molecular targets frequently generate dense continuation filing activity — a pattern visible in both the Alnylam and Neurimmune portfolios reviewed here. For a broader view of the drug discovery intelligence landscape, PatSnap’s platform aggregates patent, literature, and clinical data in a unified environment.
Neurimmune AG holds the broadest international ATTR antibody patent portfolio in the retrieved dataset, with active or pending filings across US, EP, IL, SG, NZ, JP, CA, AU, WO, and CN jurisdictions — and is the only assignee to hold explicit combination therapy claims pairing an anti-TTR antibody with a TTR tetramer stabiliser.
“Combination therapy IP is an active and underappreciated space: Neurimmune’s antibody-plus-stabiliser claims and Prothena’s multi-modality treatment history references suggest combination regimens will be a key battleground for IP ownership and clinical differentiation in the next three to five years.”
Academic assignees — including the University of Tennessee Research Foundation (diagnostics) and University Health Network (anti-TTR antibody development) — indicate ongoing academic-to-commercial translation interest in ATTR, providing potential licensing and partnership opportunities for commercial developers. The PatSnap Insights blog covers additional analyses of rare disease patent landscapes and biologic IP strategy.